ROCHE AND INTERMUNE, INC. REACH DEFINITIVE MERGER AGREEMENT

Aug 25, 2014, 11:53 AM
announcement_icn_45
PFF Comment

“The merger of Roche and InterMune is an exciting step forward for the fibrosis community. The combined resources and commitment to patients with pulmonary disease of both Roche and InterMune will likely improve the care of patients with pulmonary fibrosis and accelerate the identification of additional novel therapies for fibrotic lung disease,” said Gregory P. Cosgrove, MD, Chief Medical Officer of the Pulmonary Fibrosis Foundation. "The union between Roche, its US subsidiary Genentech, and InterMune will create an entity with exceptional scientific expertise.”  
“The Foundation looks forward to future collaborations with the merged company to enhance programs for patients with pulmonary fibrosis. The agreement between Roche and InterMune further expands the scientific and patient care resources that will advance the care of patients with pulmonary fibrosis,” PFF President and COO Patti Tuomey, EdD, said.

View Announcement
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >